Skip to main content
Top

Open Access 23-04-2024 | Atopic Dermatitis | Original Research

Economic Burden of Itch-Related Sleep Loss in Moderate-to-Severe Atopic Dermatitis in the United Kingdom

Authors: Evangeline J. Pierce, Russel T. Burge, Alex J. Hirst, Aimée M. Fox, Anu K. Suokas, Yunni Yi

Published in: Dermatology and Therapy

Login to get access

Abstract

Introduction

Atopic dermatitis is associated with intense itch, which has been shown to cause sleep disruption that significantly impacts the lives of patients with atopic dermatitis. Despite this, little is known about its burden to the healthcare system and society. This study aimed to quantify the economic burden of itch-related sleep loss in moderate-to-severe atopic dermatitis in the UK.

Methods

A literature-based decision-analytic model was developed from a healthcare payer and societal perspective. The model quantifies the economic burden by linking the severity of itch to the number of days of sleep disruption. The model captures the direct costs of healthcare resource utilization and treatment alongside the indirect costs of productivity loss from absenteeism and presenteeism at work over a 5-year time horizon. The patient population considered was patients aged ≥ 15 years with moderate-to-severe atopic dermatitis and itch-related sleep disruption.

Results

The model estimated that itch-related sleep disruption as a result of moderate-to-severe atopic dermatitis would affect an average of 821,142 people over the time horizon (2022 to 2026). This translates into an average net economic burden of £3.8 billion (£4687 per patient), with an average of 172 million days being affected by sleep disruption per year in the UK. The greatest contributor to the annual average net economic burden was productivity loss from absenteeism and presenteeism, each accounting for 34%. The direct costs (treatment costs and healthcare resource use) accounted for 32% of the net economic burden. The results showed a high and gradually increasing economic burden over the 5-year time horizon.

Conclusions

Sleep disruption has a high economic burden and reducing itch may provide substantial direct and indirect savings. Quantifying the economic burden of itch-related sleep loss may provide support for analyses to inform public health policies for treatment of atopic dermatitis, particularly within the moderate-to-severe level.
Appendix
Available only for authorised users
Literature
2.
go back to reference Cork MJ, Danby SG, Ogg GS. Atopic dermatitis epidemiology and unmet need in the United Kingdom. Oxford: Taylor & Francis Group; 2019. Cork MJ, Danby SG, Ogg GS. Atopic dermatitis epidemiology and unmet need in the United Kingdom. Oxford: Taylor & Francis Group; 2019.
3.
go back to reference Barbarot S, Auziere S, Gadkari A, Girolomoni G, Puig L, Simpson EL, et al. Epidemiology of atopic dermatitis in adults: results from an international survey. Allergy. 2018;73(6):1284–93.CrossRefPubMed Barbarot S, Auziere S, Gadkari A, Girolomoni G, Puig L, Simpson EL, et al. Epidemiology of atopic dermatitis in adults: results from an international survey. Allergy. 2018;73(6):1284–93.CrossRefPubMed
4.
go back to reference Girolomoni G, Luger T, Nosbaum A, Gruben D, Romero W, Llamado LJ, et al. The economic and psychosocial comorbidity burden among adults with moderate-to-severe atopic dermatitis in Europe: analysis of a cross-sectional survey. Dermatol Ther (Heidelb). 2021;11(1):117–30.CrossRefPubMed Girolomoni G, Luger T, Nosbaum A, Gruben D, Romero W, Llamado LJ, et al. The economic and psychosocial comorbidity burden among adults with moderate-to-severe atopic dermatitis in Europe: analysis of a cross-sectional survey. Dermatol Ther (Heidelb). 2021;11(1):117–30.CrossRefPubMed
5.
go back to reference Kwatra SG, Gruben D, Fung S, DiBonaventura M. Psychosocial comorbidities and health status among adults with moderate-to-severe atopic dermatitis: a 2017 US National Health and Wellness Survey Analysis. Adv Ther. 2021;38(3):1627–37.CrossRefPubMedPubMedCentral Kwatra SG, Gruben D, Fung S, DiBonaventura M. Psychosocial comorbidities and health status among adults with moderate-to-severe atopic dermatitis: a 2017 US National Health and Wellness Survey Analysis. Adv Ther. 2021;38(3):1627–37.CrossRefPubMedPubMedCentral
7.
go back to reference Bruin-Weller M, Pink AE, Patrizi A, Gimenez-Arnau AM, Agner T, Roquet-Gravy PP, et al. Disease burden and treatment history among adults with atopic dermatitis receiving systemic therapy: baseline characteristics of participants on the EUROSTAD prospective observational study. J Dermatolog Treat. 2021;32(2):164–73.CrossRefPubMed Bruin-Weller M, Pink AE, Patrizi A, Gimenez-Arnau AM, Agner T, Roquet-Gravy PP, et al. Disease burden and treatment history among adults with atopic dermatitis receiving systemic therapy: baseline characteristics of participants on the EUROSTAD prospective observational study. J Dermatolog Treat. 2021;32(2):164–73.CrossRefPubMed
8.
go back to reference Medic G, Wille M, Hemels EH.M. Short- and long-term health consequences of sleep disruption. Nature and Science of Sleep. 2017. Medic G, Wille M, Hemels EH.M. Short- and long-term health consequences of sleep disruption. Nature and Science of Sleep. 2017.
11.
go back to reference Gooderham M, Ständer S, Szepietowski J, Girolomoni G, Bushmakin A, Cappelleri J, et al., editors. Interpreting the Relationship Among Pruritus, Sleep, and Work Productivity: Results From JADE MONO-2. American Academy of Dermatology (AAD) VMX Virtual Meeting Experience, April 23–25; 2021. Gooderham M, Ständer S, Szepietowski J, Girolomoni G, Bushmakin A, Cappelleri J, et al., editors. Interpreting the Relationship Among Pruritus, Sleep, and Work Productivity: Results From JADE MONO-2. American Academy of Dermatology (AAD) VMX Virtual Meeting Experience, April 23–25; 2021.
15.
go back to reference Pascal C, Maucort-Boulch D, Gilibert S, Bottigioli D, Verdu V, Jaulent C, et al. Therapeutic management of adults with atopic dermatitis: comparison with psoriasis and chronic urticaria. J Eur Acad Dermatol Venereol. 2020;34(10):2339–45.CrossRefPubMed Pascal C, Maucort-Boulch D, Gilibert S, Bottigioli D, Verdu V, Jaulent C, et al. Therapeutic management of adults with atopic dermatitis: comparison with psoriasis and chronic urticaria. J Eur Acad Dermatol Venereol. 2020;34(10):2339–45.CrossRefPubMed
19.
go back to reference Toron F, Neary M, Smith T, Gruben D, Romero W, Cha A, et al. Clinical and economic burden of mild-to-moderate atopic dermatitis in the UK: a propensity-score-matched case-control study. Dermatol Ther (Heidelb). 2021;11(3):907–28.CrossRefPubMed Toron F, Neary M, Smith T, Gruben D, Romero W, Cha A, et al. Clinical and economic burden of mild-to-moderate atopic dermatitis in the UK: a propensity-score-matched case-control study. Dermatol Ther (Heidelb). 2021;11(3):907–28.CrossRefPubMed
Metadata
Title
Economic Burden of Itch-Related Sleep Loss in Moderate-to-Severe Atopic Dermatitis in the United Kingdom
Authors
Evangeline J. Pierce
Russel T. Burge
Alex J. Hirst
Aimée M. Fox
Anu K. Suokas
Yunni Yi
Publication date
23-04-2024
Publisher
Springer Healthcare
Published in
Dermatology and Therapy
Print ISSN: 2193-8210
Electronic ISSN: 2190-9172
DOI
https://doi.org/10.1007/s13555-024-01153-9
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.